Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer

BACKGROUND: The recent approval of olaparib and niraparib as maintenance therapy can significantly affect the management of ovarian cancer. Clinical benefits, however, come with trade-offs in adverse events and costs. OBJECTIVE: To evaluate the cost-effectiveness of new ovarian cancer poly-ADP ribos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lixian, Tran, Anh Thu, Tomasino, Taylor, Nugent, Elizabeth, Smith, Judith A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397875/
https://www.ncbi.nlm.nih.gov/pubmed/30479195
http://dx.doi.org/10.18553/jmcp.2018.24.12.1219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397875/
https://www.ncbi.nlm.nih.gov/pubmed/30479195
http://dx.doi.org/10.18553/jmcp.2018.24.12.1219

Ejemplares similares